Amphastar Pharma (AMPH) Misses Q2 EPS by 4c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $71 million versus the consensus estimate of $62.9 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Bristow Group to acquire Berry Aviation for $105 million